© 2005 European Society of Cardiology
The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters
a Cardiology Department, Western Attica General Hospital Athens, Greece
b Social Security Institution, Piraeus Unit Greece
* Corresponding author. Tel.: +30 210 8041601; fax: +30 210 5698465. E-mail address: nikoskou{at}otenet.gr
 |
Abstract |
|---|
Objective: To assess serum levels of carbohydrate antigen 125 (CA125) in patients with chronic congestive heart failure (CHF) and to assess any correlation with clinical symptoms and echocardiographic indices.
Patients and methods: We enrolled 77 male patients (mean age: 73±10 years) admitted to the Cardiology Emergency Department (ED) with cardiac symptoms requiring hospitalization. Diagnosis of CHF was based upon medical history or initial echocardiographic evaluation on current admission. Serum CA125 was measured by an enzyme immunoradiometric assay, on admission and before discharge.
Results: The median overall CA125 value was 22.4 (11.5–48.9) U/ml. Serum CA125 levels were related to the severity of CHF [New York Heart Association (NYHA) class I: 19.2 (7.2–31) U/ml, NYHA class II: 17.6 (10–23) U/ml, NYHA class III: 32 (25–77) U/ml and NYHA class IV: 34.3 (18.6–77) U/ml (p<0.04)]. Patients in NYHA classes III and IV had significantly higher mean values of CA125, than patients in class II (p<0.005 and p<0.05, respectively). Moreover, patients with fluid congestion (pulmonary congestion, ankle edema) had higher levels of serum CA125 than patients without congestion (p=0.002 and p<0.03, respectively). Finally, levels of serum CA125 correlated weakly with right ventricular systolic pressure (RVSP) and renal function, while no significant correlation was found between CA125 and E wave deceleration time on Doppler echocardiography, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), liver function and the medical treatment prescribed.
Conclusion: Serum CA125 is associated with the clinical severity of CHF and the symptoms and signs of fluid congestion and therefore may be a useful additional tool for the evaluation and clinical staging of these patients.
Key Words: Tumor marker • CA125 • Congestive heart failure
Received July 29, 2003; Revised December 16, 2003; Accepted July 5, 2004
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Duman, F. Palit, E. Simsek, and K. Bilgehan Serum carbohydrate antigen 125 levels in advanced heart failure: Relation to B-type natriuretic peptide and left atrial volume Eur J Heart Fail, June 1, 2008; 10(6): 556 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nunez, E. Nunez, L. Consuegra, J. Sanchis, V. Bodi, A. Martinez-Brotons, V. Bertomeu-Gonzalez, R. Robles, M. J Bosch, L. Facila, et al. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart, June 1, 2007; 93(6): 716 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kosar, Y. Aksoy, G. Ozguntekin, I. Ozerol, and E. Varol Relationship between cytokines and tumour markers in patients with chronic heart failure Eur J Heart Fail, May 1, 2006; 8(3): 270 - 274. [Abstract] [Full Text] [PDF]
|
|